Combination Nasal Spray Demonstrates Results in Treating Children with Seasonal Allergic Rhinitis – Drug for nerve pain boosts high for opioid abusers. (866) 348-2889
Positive results were collected from a Phase 3 study of an investigational fixed-dose combination nasal spray for the treatment of seasonal allergic rhinitis (SAR), according to Glenmark Pharmaceuticals.
The olopatadine hydrochloride [665 mcg] and mometasone furoate [25 mcg] nasal spray (Ryaltris, Glenmark) has been conditionally accepted by the FDA.
Also known as GSP 301 Nasal Spray, the drug met its primary endpoint in achieving clinically meaningful and statistically significant change from baseline in average morning and evening Reflective Total Nasal Symptom Score (rTNSS) compared to placebo in patients aged 6 years to under 12 years that participated in the study, according to Glenmark.